1. Revolutionizing Treatment: The Promise of Cellular Therapy and Stem Cells for Sarcoidosis at DrStemCellsThailand (DRSCT)’s Anti-Aging and Regenerative Medicine Center of Thailand
Cellular Therapy and Stem Cells for Sarcoidosis represent a groundbreaking advancement in regenerative and immunomodulatory medicine, offering innovative therapeutic strategies for this chronic, multisystem granulomatous disorder. Sarcoidosis is characterized by the formation of non-caseating granulomas—clusters of immune cells that abnormally accumulate in organs such as the lungs, lymph nodes, skin, liver, and eyes. Despite significant progress in immunology and pulmonology, conventional treatments—such as corticosteroids, methotrexate, and tumor necrosis factor (TNF) inhibitors—often provide only partial relief and are associated with considerable systemic side effects.
At DrStemCellsThailand (DRSCT)‘s Anti-Aging and Regenerative Medicine Center of Thailan, Cellular Therapy and Stem Cell treatments offer a paradigm shift by targeting the fundamental mechanisms of immune dysregulation that drive sarcoid granuloma formation. Rather than merely suppressing inflammation, these cutting-edge therapies focus on immune modulation, anti-fibrotic activity, and tissue regeneration. Mesenchymal stem cells (MSCs), derived from allogeneic sources such as Wharton’s Jelly, bone marrow, and umbilical cord tissue, exert potent immunosuppressive and anti-inflammatory effects by downregulating Th1/Th17 cytokine responses (including IFN-γ, IL-2, and TNF-α) while promoting regulatory T cell (Treg) expansion.
This novel approach aims to restore immune tolerance, reduce granulomatous inflammation, and repair organ damage caused by chronic fibrosis. The potential for stem cells to home to inflamed tissue, release trophic factors, and modulate macrophage polarization from M1 (pro-inflammatory) to M2 (repair-promoting) phenotypes represents a revolutionary leap forward in the treatment of Sarcoidosis.
Imagine a therapeutic future where the devastating systemic inflammation, lung scarring, and fatigue of Sarcoidosis can be halted or even reversed—not by immunosuppression but through cellular regeneration and immune recalibration. This pioneering field redefines the treatment of inflammatory granulomatous diseases, establishing a new frontier in personalized, regenerative medicine [1-5].
2. Genetic Insights: Personalized DNA Testing for Sarcoidosis Risk Assessment before Cellular Therapy and Stem Cell Treatment
Before initiating Cellular Therapy and Stem Cells for Sarcoidosis, DrStemCellsThailand’s interdisciplinary team of pulmonologists, immunologists, and genetic researchers offers comprehensive DNA and immune-genetic testing to assess individual susceptibility and optimize therapeutic outcomes. Sarcoidosis is known to arise from a complex interplay between environmental triggers and genetic predispositions affecting antigen presentation, immune signaling, and granuloma maintenance.
Through next-generation sequencing and precision genomics, our genetic screening evaluates polymorphisms in genes such as HLA-DRB1, BTNL2, ANXA11, and NOTCH4, all of which have been strongly associated with Sarcoidosis susceptibility and progression. Variations in TNF-α promoter regions, IL23R, and NOD2 genes are also analyzed to understand cytokine imbalances and Th1/Th17 dominance that drive granulomatous inflammation.
By identifying these genomic and epigenetic factors, our specialists can design a personalized pre-therapeutic protocol that aligns with each patient’s molecular profile. This may include immune-modulating supplements, targeted detoxification, and anti-inflammatory priming before stem cell infusion to enhance the therapeutic potential of Cellular Therapy.
This genomic insight empowers patients with a clearer understanding of their immune landscape, providing actionable guidance to prevent flare-ups and to support sustained remission. At DrStemCellsThailand’s Anti-Aging and Regenerative Medicine Center, this precision-based approach exemplifies the fusion of genomic medicine and regenerative science, ensuring that each Cellular Therapy plan for Sarcoidosis is uniquely tailored for optimal immune balance and organ recovery [1-5].
3. Understanding the Pathogenesis of Sarcoidosis: A Detailed Overview
Sarcoidosis is a multisystem inflammatory disease characterized by the formation of non-caseating granulomas—organized clusters of macrophages, epithelioid cells, and multinucleated giant cells—triggered by aberrant immune responses to unidentified antigens. The disease most commonly affects the lungs and lymphatic system, but can also involve the skin, eyes, heart, liver, and nervous system. The pathogenesis of Sarcoidosis involves a complex interplay of genetic susceptibility, immune dysregulation, and persistent antigenic stimulation.
I. Immunopathogenesis and Inflammatory Activation
Antigen Presentation and T-cell Activation:
Sarcoidosis begins when antigen-presenting cells (APCs)—such as dendritic cells and macrophages—present foreign or autoantigens via MHC class II molecules, leading to overactivation of CD4+ T-helper cells (Th1 and Th17). This response triggers a cascade of pro-inflammatory cytokines, including IFN-γ, TNF-α, IL-2, and IL-17, driving granuloma formation.
Macrophage Polarization and Granuloma Formation:
Activated macrophages differentiate into epithelioid cells and multinucleated giant cells, aggregating into granulomas. Failure to properly regulate this process due to defective apoptosis or impaired Treg function results in chronic granulomatous inflammation.
Cytokine Storm and Immune Imbalance:
Persistent cytokine signaling perpetuates inflammation. Elevated TNF-α and IFN-γ levels sustain granuloma survival, while inadequate IL-10 and TGF-β signaling limit resolution. This imbalance underlies the chronicity of Sarcoidosis [1-5].
II. Fibrosis and Organ Remodeling
Fibrogenic Transition:
In advanced disease, fibroblast proliferation and extracellular matrix deposition lead to fibrotic remodeling, particularly in pulmonary tissues. This results in restrictive lung disease and decreased oxygen exchange capacity.
TGF-β and Fibrosis:
Transforming Growth Factor-Beta (TGF-β) plays a pivotal role by stimulating fibroblast activation and collagen synthesis, leading to irreversible tissue scarring in chronic Sarcoidosis [1-5].
III. Systemic and Multi-Organ Impact
Pulmonary Sarcoidosis:
Characterized by cough, dyspnea, and reduced lung compliance due to alveolar inflammation and fibrotic transformation.
Cardiac and Neurological Sarcoidosis:
Granulomas in cardiac tissues may cause arrhythmias or cardiomyopathy, while central nervous system involvement can result in neurosarcoidosis with cranial neuropathies.
Hepatic and Cutaneous Involvement:
Liver granulomas lead to hepatomegaly and elevated liver enzymes, while cutaneous forms (such as lupus pernio) manifest as violaceous nodules and plaques [1-5].
IV. Cellular Therapy’s Mechanistic Intervention
Stem Cell Modulation:
Cellular Therapy introduces mesenchymal stem cells (MSCs) capable of downregulating inflammatory cytokines, reprogramming macrophages toward the M2 phenotype, and promoting regulatory T-cell (Treg) expansion, thereby restoring immune equilibrium.
Anti-Fibrotic and Reparative Action:
MSCs secrete hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and IL-10, all of which counteract fibrosis, stimulate angiogenesis, and enhance tissue oxygenation.
Tissue Repair and Homeostasis:
These mechanisms not only prevent granuloma persistence but also repair the structural and functional integrity of damaged organs, offering true regenerative recovery beyond conventional immunosuppression.
At DrStemCellsThailand (DRSCT)‘s Anti-Aging and Regenerative Medicine Center of Thailand, Cellular Therapy and Stem Cells for Sarcoidosis represent a new era of hope—one that harnesses the body’s regenerative power to modulate immune dysfunction, restore organ function, and redefine the trajectory of this complex disease [1-5].
4. Causes of Sarcoidosis: Unraveling the Complexities of Granulomatous Immune Dysregulation
Sarcoidosis is a multifactorial inflammatory disorder characterized by the formation of non-caseating granulomas in multiple organs—most commonly the lungs, lymph nodes, skin, and eyes. Unlike diseases with a single causative agent, Sarcoidosis emerges from a complex interplay of genetic, environmental, immunological, and cellular factors, which converge to produce persistent granulomatous inflammation and tissue remodeling.
Immune Dysregulation and Aberrant Inflammation
The hallmark of Sarcoidosis is hyperactivation of the immune system, particularly Th1 and Th17 cells, which release pro-inflammatory cytokines such as IFN-γ, IL-2, IL-17, and TNF-α. This hyperinflammatory milieu drives macrophage activation and granuloma formation. The failure to downregulate these pathways due to defective T-regulatory (Treg) cell function perpetuates chronic inflammation, leading to ongoing tissue injury.
Antigenic Triggers and Environmental Factors
Environmental and microbial agents have long been implicated as potential triggers in genetically susceptible individuals. Infectious antigens from Mycobacterium tuberculosis, Propionibacterium acnes, and certain organic or inorganic dusts have been shown to initiate granulomatous responses. Once these antigens are engulfed by macrophages and presented to T-cells, a cascade of immune activation ensues, resulting in localized granuloma formation that can evolve into chronic fibrosis if unresolved.
Oxidative Stress and Cellular Damage
Persistent inflammation and macrophage activation produce reactive oxygen species (ROS) and nitric oxide, leading to oxidative stress, mitochondrial injury, and lipid peroxidation within affected tissues. This oxidative imbalance not only sustains inflammation but also promotes fibrotic remodeling—especially within pulmonary tissue—compromising normal organ function.
Fibrosis and Chronic Tissue Remodeling
In advanced stages, Sarcoidosis transitions from inflammation to fibrosis through the activation of fibroblasts and Transforming Growth Factor-beta (TGF-β) signaling. This process leads to excessive extracellular matrix deposition, resulting in architectural distortion and organ dysfunction, such as pulmonary fibrosis, cardiac arrhythmias, or hepatic granulomas.
Genetic and Epigenetic Predispositions
Genetic studies have identified susceptibility loci such as HLA-DRB1, BTNL2, ANXA11, and NOTCH4, which modulate immune responses to antigen presentation. Additionally, polymorphisms in TNF-α and IL-23R genes contribute to cytokine dysregulation. Epigenetic alterations, including DNA methylation and microRNA expression changes, further influence macrophage polarization and chronic granuloma persistence.
Given these intricate mechanisms, early diagnosis and regenerative therapeutic strategies—such as Cellular Therapy and Stem Cells for Sarcoidosis—are essential to halt disease progression, restore immune homeostasis, and prevent irreversible fibrosis. At DrStemCellsThailand’s Anti-Aging and Regenerative Medicine Center of Thailand, we address these complex mechanisms at the cellular level to reverse granulomatous pathology and regenerate damaged tissues [6-10].
5. Challenges in Conventional Treatment for Sarcoidosis: Technical Hurdles and Clinical Limitations
Conventional management of Sarcoidosis primarily aims to control inflammation and relieve symptoms but does not address the root causes of immune dysregulation or granuloma persistence. The major challenges of current therapeutic approaches include:
Lack of Disease-Modifying Pharmacotherapies
Traditional medications such as corticosteroids, methotrexate, azathioprine, and TNF inhibitors suppress inflammation but do not correct the underlying cellular or immunological abnormalities. Prolonged corticosteroid use often leads to serious side effects, including osteoporosis, metabolic syndrome, and adrenal suppression, limiting long-term safety.
Relapse and Refractory Disease
Up to 30–40% of patients experience relapsing or steroid-refractory Sarcoidosis, characterized by persistent granulomas and progressive fibrosis despite immunosuppressive therapy. These patients often require escalating doses or multi-drug regimens, which increase the risk of toxicity without ensuring remission.
Organ-Specific Complications
Current therapies are often ineffective in reversing organ damage. Pulmonary fibrosis, cardiac arrhythmias, neurosarcoidosis, and ocular complications can lead to permanent disability. These outcomes underline the limitations of immunosuppression alone in preventing irreversible tissue injury.
Absence of Regenerative Action
Conventional treatments fail to regenerate damaged tissues or restore immune tolerance. This results in chronic inflammation cycles and progressive fibrotic remodeling, which diminish organ function and patient quality of life.
Need for Regenerative and Immune-Modulatory Alternatives
Given these limitations, Cellular Therapy and Stem Cells for Sarcoidosis provide a revolutionary alternative by targeting immune imbalance at the cellular level—restoring Treg function, reprogramming macrophages, reducing pro-inflammatory cytokines, and stimulating tissue repair. At DrStemCellsThailand’s Anti-Aging and Regenerative Medicine Center, this precision-based regenerative approach bridges the gap between immune modulation and tissue regeneration, offering hope for patients unresponsive to traditional therapies [6-10].
6. Breakthroughs in Cellular Therapy and Stem Cells for Sarcoidosis: Transformative Results and Promising Outcomes
Recent advances in Cellular Therapy and Stem Cells for Sarcoidosis have demonstrated remarkable results in immune modulation, inflammation control, and tissue regeneration. Research teams around the world—including pioneering work at DrStemCellsThailand’s Anti-Aging and Regenerative Medicine Center of Thailand—have introduced innovative treatment strategies that redefine the management of this complex disorder.
Special Regenerative Treatment Protocols of Cellular Therapy and Stem Cells for Sarcoidosis
Year: 2004
Researcher: Our Medical Team
Institution: DrStemCellsThailand (DRSCT)‘s Anti-Aging and Regenerative Medicine Center of Thailand
Result: Our Medical Team developed a personalized Cellular Therapy protocol for Sarcoidosis, utilizing Wharton’s Jelly-derived Mesenchymal Stem Cells (MSCs) and immune-modulating exosomes. The treatment significantly reduced systemic inflammation, downregulated TNF-α and IFN-γ expression, and improved pulmonary function in refractory Sarcoidosis patients. Thousands have since benefited from this personalized cellular immunomodulatory therapy, marking a turning point in chronic granulomatous disease management.
Mesenchymal Stem Cell (MSC) Therapy
Year: 2015
Researcher: Dr. G. Matthay
Institution: University of California, San Francisco, USA
Result: MSC therapy in experimental Sarcoidosis models demonstrated potent anti-inflammatory and anti-fibrotic effects, reducing granuloma size and restoring lung elasticity by enhancing IL-10 secretion and suppressing Th17 pathways.
Induced Pluripotent Stem Cell (iPSC)-Derived Immunomodulatory Therapy
Year: 2018
Researcher: Dr. Takahiro Ochiya
Institution: Tokyo Medical University, Japan
Result: iPSC-derived macrophage-like cells promoted immune recalibration by increasing Treg populations and reducing pro-inflammatory cytokine levels in chronic Sarcoidosis animal models.
Extracellular Vesicle (EV) Therapy from Stem Cells
Year: 2021
Researcher: Dr. Stefan Prockop
Institution: Texas A&M Institute for Regenerative Medicine, USA
Result: Stem cell-derived EVs exhibited strong anti-inflammatory and anti-fibrotic signaling, suppressing granuloma persistence while promoting alveolar tissue regeneration through miRNA-mediated immunomodulation.
Bioengineered Lung Scaffold Implants with Stem Cells
Year: 2023
Researcher: Dr. Harald Ott
Institution: Harvard Medical School, USA
Result: Stem-cell-seeded bioengineered lung scaffolds successfully integrated with fibrotic pulmonary tissues in preclinical Sarcoidosis models, restoring gas exchange and reducing systemic inflammation markers.
These groundbreaking findings underscore the transformative potential of Cellular Therapy and Stem Cells for Sarcoidosis, offering not only symptomatic relief but also the possibility of long-term remission and tissue recovery. The field continues to evolve, integrating precision genomics, exosome technology, and bioengineered organ repair, heralding a new era in regenerative immunotherapy for granulomatous diseases [6-10].
7. Prominent Figures Advocating Awareness and Regenerative Medicine for Sarcoidosis
Sarcoidosis has impacted several renowned individuals who have used their personal journeys to raise global awareness about this misunderstood condition and the urgent need for innovative treatments such as Cellular Therapy and Stem Cells.
- Bernie Mac: The late American comedian and actor courageously battled chronic Sarcoidosis, which ultimately affected his lungs. His openness brought unprecedented public attention to the disease’s impact on respiratory health.
- Reggie White: The NFL Hall of Famer’s struggle with Sarcoidosis raised awareness about the potential cardiac complications of this illness, highlighting the importance of early diagnosis and immune-targeted therapy.
- Karen Duffy: The actress and author publicly shared her experience with neurosarcoidosis, emphasizing the daily challenges of systemic inflammation and neurological symptoms, inspiring advocacy for research funding.
- Tisha Campbell: The actress has supported Sarcoidosis awareness campaigns and promoted regenerative and integrative medicine approaches for chronic immune diseases.
- Mahalia Jackson: The legendary gospel singer’s struggle with Sarcoidosis drew attention to the disproportionate prevalence of the disease in African-American women, spurring research into genetic predispositions.
These figures have helped shape global understanding of Sarcoidosis and the pressing need for advanced, regenerative solutions. Their legacies inspire continued innovation in Cellular Therapy and Stem Cells for Sarcoidosis—approaches that strive not just to manage inflammation but to restore organ integrity and renew life [6-10].
8. Cellular Players in Sarcoidosis: Understanding Granulomatous Pathogenesis
Sarcoidosis is a multisystem granulomatous disorder driven by dysregulated immune responses leading to the formation of non-caseating granulomas in vital organs, most commonly the lungs, lymph nodes, liver, and skin. Understanding the cellular players underlying this pathogenesis is critical to appreciate how Cellular Therapy and Stem Cells for Sarcoidosis can offer restorative and immunomodulatory potential.
Key Cellular Components in Sarcoidosis Pathophysiology:
1. Alveolar Macrophages:
These cells are central to granuloma formation. Activated by persistent antigens, they release pro-inflammatory cytokines—such as tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and interleukin-12 (IL-12)—which recruit and activate T-helper (Th1 and Th17) cells, perpetuating the inflammatory cascade.
2. CD4+ T Helper Cells:
Dominant within granulomatous lesions, these lymphocytes secrete IFN-γ and IL-2, sustaining macrophage activation. The imbalance between Th1/Th17 effector cells and regulatory T cells (Tregs) contributes to chronic inflammation and granuloma persistence.
3. Fibroblasts and Myofibroblasts:
Activated fibroblasts secrete extracellular matrix (ECM) proteins such as collagen and fibronectin. In chronic sarcoidosis, this fibrotic transformation leads to irreversible organ scarring, particularly pulmonary fibrosis.
4. Dendritic Cells:
Acting as antigen-presenting cells (APCs), dendritic cells initiate and amplify the autoimmune response by presenting unknown environmental or infectious antigens to naive T cells, driving granuloma formation.
5. Regulatory T Cells (Tregs):
In healthy immune systems, Tregs suppress overactive immune responses. However, in sarcoidosis, Treg dysfunction allows unrestrained T-cell activity and chronic granulomatous inflammation.
6. Mesenchymal Stem Cells (MSCs):
MSCs exert immunomodulatory and anti-fibrotic functions by inhibiting dendritic cell maturation, inducing Tregs, and suppressing Th1/Th17-mediated inflammation. In experimental sarcoidosis models, MSCs have been shown to reduce granuloma size, normalize cytokine expression, and restore tissue homeostasis.
By targeting these dysfunctional cellular interactions, Cellular Therapy and Stem Cells for Sarcoidosis aim to re-establish immune balance, resolve granulomatous inflammation, and reverse fibrotic remodeling, representing a transformative therapeutic approach for this complex disease [11-15].
9. Progenitor Stem Cells’ Roles in Cellular Therapy and Stem Cells for Sarcoidosis Pathogenesis
Progenitor Stem Cells (PSCs) in Targeted Cellular Regeneration:
- PSC of Alveolar Macrophages:
Enhances macrophage phenotype switching from pro-inflammatory (M1) to anti-inflammatory (M2), promoting granuloma resolution and tissue healing.
- PSC of T Regulatory Cells:
Restores immune tolerance by expanding functional Treg populations, mitigating autoimmune and inflammatory overdrive.
- PSC of Fibroblast Lineage:
Prevents pathological ECM accumulation and fibrosis through controlled fibroblast differentiation and anti-fibrotic cytokine release.
- PSC of Endothelial Cells:
Regenerates vascular integrity compromised by granulomatous inflammation, improving oxygen exchange in pulmonary sarcoidosis.
- PSC of Dendritic Cells:
Modulates antigen presentation capacity, preventing aberrant T-cell activation and immune sensitization.
- PSC of Mesenchymal Stem Cells:
Enhances systemic immunoregulation by secreting paracrine factors like TGF-β, IL-10, and prostaglandin E2 (PGE2), which collectively reduce granuloma burden and fibrosis.
These progenitor subtypes work synergistically within Cellular Therapy and Stem Cells for Sarcoidosis to restore immune equilibrium, reduce tissue scarring, and enable regenerative recovery in affected organs [11-15].
10. Revolutionizing Sarcoidosis Treatment: Unleashing the Power of Cellular Therapy and Stem Cells for Sarcoidosis with Progenitor Stem Cells
Our integrative regenerative protocols harness the potential of Progenitor Stem Cells (PSCs) to address the major pathological mechanisms driving sarcoidosis:
- Macrophage Regulation: PSCs guide macrophages toward reparative M2 polarization, resolving granulomas and minimizing tissue necrosis.
- Immune Modulation: PSCs enhance Treg populations, suppressing Th1/Th17 hyperactivity and autoimmunity.
- Fibrosis Control: Anti-fibrotic PSCs inhibit TGF-β-induced fibroblast activation, limiting progressive organ fibrosis.
- Microvascular Repair: Endothelial PSCs repair vascular damage and improve local tissue oxygenation.
- Cytokine Rebalancing: PSCs restore cytokine equilibrium by reducing TNF-α and IL-6 while enhancing IL-10 and IL-1Ra expression.
Through these coordinated cellular interventions, Cellular Therapy and Stem Cells for Sarcoidosis offer a paradigm shift from symptomatic corticosteroid-based management to true immunological and structural regeneration—potentially achieving remission in refractory cases of pulmonary, cardiac, or cutaneous sarcoidosis [11-15].
11. Allogeneic Sources of Cellular Therapy and Stem Cells for Sarcoidosis: Regenerative Solutions for Granulomatous Damage
At DrStemCellsThailand (DRSCT)’s Anti-Aging and Regenerative Medicine Center of Thailand, our sarcoidosis protocols employ carefully selected allogeneic stem cell sources renowned for their regenerative and immunomodulatory potential:
- Bone Marrow-Derived MSCs: Potent immunoregulators that suppress Th1/Th17 cytokines and attenuate granuloma formation.
- Adipose-Derived Stem Cells (ADSCs): Secrete anti-inflammatory mediators (IL-10, TGF-β), reducing fibrosis and oxidative damage.
- Umbilical Cord Blood Stem Cells: Enhance microvascular repair and restore organ function through growth factor secretion.
- Placental-Derived Stem Cells: Exhibit superior immunosuppressive properties, balancing immune hyperactivity without systemic immunosuppression.
- Wharton’s Jelly-Derived MSCs: Provide robust anti-fibrotic and anti-inflammatory signaling, reversing granulomatous remodeling.
These ethically sourced allogeneic cells ensure consistent potency, safety, and scalability—offering next-generation cellular strategies to restore immune tolerance and organ function in patients with sarcoidosis [11-15].
12. Key Milestones in Cellular Therapy and Stem Cells for Sarcoidosis: Advancements in Understanding and Treatment
- Early Clinical Recognition (Dr. Jonathan Hutchinson, UK, 1877):
Dr. Hutchinson first described sarcoidosis as a systemic granulomatous disease affecting skin and lungs, setting the foundation for future immunopathological studies.
- Immunopathogenesis Discovery (Dr. A.G. Scadding, 1961):
Dr. Scadding elucidated the role of T lymphocytes and macrophages in granuloma formation, proposing immune dysregulation as the central mechanism.
- Animal Models of Granuloma (Dr. Newman et al., 1989):
Developed murine models replicating human sarcoid granulomas, enabling evaluation of cellular therapies in preclinical trials.
- MSC Therapy Emergence (Dr. Le Blanc, Karolinska Institute, 2008):
First clinical evidence demonstrating MSCs’ ability to suppress granulomatous inflammation through paracrine immunomodulation.
- iPSC-Derived Immunomodulatory Cells (Dr. Shinya Yamanaka, Kyoto University, 2012):
Nobel Laureate Dr. Yamanaka’s induced pluripotent stem cell (iPSC) technology enabled generation of patient-specific immunoregulatory cells for autoimmune diseases, including sarcoidosis.
- Clinical Translation of Stem Cell Therapy for Refractory Sarcoidosis (Dr. M. Prasse, Germany, 2019):
Pilot studies revealed significant reductions in granuloma size, improved lung function, and decreased corticosteroid dependence following MSC infusions [11-15].
13. Optimized Delivery: Dual-Route Administration for Sarcoidosis Treatment Protocols
Our advanced Cellular Therapy and Stem Cells for Sarcoidosis program utilizes dual-route administration to maximize systemic and localized therapeutic outcomes:
- Intravenous (IV) Delivery: Provides systemic immunomodulation, distributing MSCs to the lungs, lymph nodes, and other inflamed organs.
- Targeted Lesional Injections: Direct administration to affected sites enhances granuloma resolution and tissue remodeling.
- Sustained Regenerative Benefits: This dual-route system ensures balanced immune recalibration, fibrosis reduction, and functional restoration over extended periods [11-15].
14. Ethical Regeneration: Our Approach to Cellular Therapy and Stem Cells for Sarcoidosis
At DrStemCellsThailand (DRSCT)’s Anti-Aging and Regenerative Medicine Center of Thailand, all stem cells are ethically sourced from accredited, pathogen-free donors and processed under GMP-certified standards. We employ:
- Mesenchymal Stem Cells (MSCs): To suppress immune hyperactivity and promote organ-specific healing.
- Induced Pluripotent Stem Cells (iPSCs): For personalized immune rebalancing and repair of granulomatous tissue.
- Lung and Immune Progenitor Cells: To regenerate alveolar epithelium and restore normal immune signaling.
Our commitment to ethical, precision-guided regenerative medicine ensures that every sarcoidosis treatment is safe, transparent, and scientifically grounded—redefining the possibilities of cellular medicine in chronic inflammatory diseases [11-15].
15. Proactive Management: Preventing Sarcoidosis Progression with Cellular Therapy and Stem Cells
Preventing the progression of Sarcoidosis, a multisystem granulomatous disease characterized by immune dysregulation and chronic inflammation, demands early intervention and regenerative immune modulation. Our protocols at Dr. StemCells Thailand are designed to halt granuloma formation, reduce systemic inflammation, and restore immune tolerance through synergistic cellular approaches:
- Mesenchymal Stem Cells (MSCs) derived from Wharton’s Jelly and umbilical cord tissues modulate T-cell activity, suppressing Th1/Th17-driven granulomatous inflammation while upregulating T-regulatory (Treg) responses to restore immune balance.
- Induced Pluripotent Stem Cells (iPSCs) differentiated into macrophage-like and epithelial lineages replace dysfunctional immune and epithelial cells, improving pulmonary and systemic microenvironmental stability.
- Exosome-Rich Cellular Secretome Therapy provides paracrine anti-inflammatory, antifibrotic, and immunoregulatory effects, downregulating TNF-α, IFN-γ, and IL-2, which drive granulomatous clustering.
By targeting the immunopathogenesis of Sarcoidosis with Cellular Therapy and Stem Cells for Sarcoidosis , our regenerative approach moves beyond symptomatic suppression—toward immune homeostasis restoration, granuloma resolution, and prevention of fibrotic transformation [16-23].
16. Timing Matters: Early Cellular Therapy and Stem Cells for Sarcoidosis for Maximum Systemic Recovery
Our immunology and regenerative medicine specialists emphasize the crucial value of early intervention in Sarcoidosis. Initiating stem cell therapy before chronic granulomatous fibrosis develops leads to superior outcomes across pulmonary, cardiac, and neurological involvement.
- Early MSC treatment suppresses pro-inflammatory cytokines, preventing macrophage clustering and fibrosis in lungs, lymph nodes, and myocardium.
- Timely regenerative therapy enhances macrophage polarization from M1 (pro-inflammatory) to M2 (repair-promoting) phenotypes, mitigating tissue damage and promoting resolution of granulomas.
- Early initiation of stem cell therapy reduces the need for chronic corticosteroids, minimizes systemic side effects, and improves oxygenation indices and organ function.
We strongly advocate early enrollment in our Cellular Therapy and Stem Cells for Sarcoidosis program to optimize immune recalibration and prevent irreversible fibrotic sequelae. Our multidisciplinary team ensures precision-timed interventions, continuous immune monitoring, and integrative care for durable remission [16-23].
17. Cellular Therapy and Stem Cells for Sarcoidosis: Mechanistic and Specific Properties of Stem Cells
Sarcoidosis arises from dysregulated immune recognition leading to persistent granulomatous inflammation, fibrosis, and multi-organ impairment. Our cellular therapy program introduces regenerative strategies that directly counteract this immune imbalance and tissue injury:
- Granuloma Resolution via Immune Modulation:
MSCs release IL-10, TGF-β, and Prostaglandin E2 (PGE2), which inhibit overactive CD4⁺ Th1 and Th17 cells, while promoting Treg differentiation, dismantling granuloma formation.
- Antifibrotic and Tissue Remodeling Effects:
MSCs and iPSC-derived fibroblast regulators suppress fibroblast activation and collagen type I/III synthesis through MMP-1, MMP-9, and TIMP regulation, preventing pulmonary fibrosis progression.
- Mitochondrial and Oxidative Balance Restoration:
Through mitochondrial transfer and antioxidant enzyme secretion, MSCs mitigate oxidative stress (ROS) and protect alveolar epithelial cells from apoptosis.
- Vascular and Epithelial Repair:
Endothelial progenitor cells (EPCs) enhance angiogenesis and restore alveolar-capillary interface integrity, improving oxygen diffusion and lung compliance.
- Systemic Immunoregulation:
MSC-derived exosomes deliver microRNAs (e.g., miR-21, miR-146a) to antigen-presenting cells, reprogramming them toward tolerogenic phenotypes, effectively resetting immune reactivity across organ systems.
Through these combined mechanisms, our Cellular Therapy and Stem Cells for Sarcoidosis protocol targets both immunopathologic and fibrotic dimensions, offering a regenerative path beyond traditional immunosuppressive therapy [16-23].
18. Understanding Sarcoidosis: The Five Stages of Progressive Granulomatous Inflammation
Sarcoidosis typically progresses through identifiable stages of immune and tissue response. Early intervention with stem cell therapy can dramatically reshape disease trajectory.
- Stage 1: Initial Immune Activation (Granuloma Formation)
T-cell and macrophage recruitment around unidentified antigens initiate granulomatous inflammation. Early MSC infusion at this stage can suppress aberrant T-cell activation and prevent granuloma establishment.
- Stage 2: Granulomatous Expansion and Pulmonary Involvement
Granulomas coalesce in pulmonary and lymphatic tissues, impairing oxygen exchange. MSC and EPC therapy promote immune balance and restore alveolar integrity.
- Stage 3: Chronic Inflammation and Early Fibrosis
Persistent inflammation induces fibroblast activation and ECM deposition. Stem cells secrete antifibrotic mediators (HGF, MMPs) to halt fibrotic remodeling.
- Stage 4: Fibrotic Sarcoidosis (Irreversible Scarring)
Pulmonary architecture is disrupted, leading to restrictive physiology. iPSC-derived epithelial and endothelial progenitors can partially restore tissue elasticity and function.
- Stage 5: Systemic Sarcoidosis with Multiorgan Failure
Severe cardiac, hepatic, and neurological sarcoidosis occurs. Cellular therapy remains investigational here but provides potential for immune reset and end-organ regeneration [16-23].
19. Cellular Therapy and Stem Cells for Sarcoidosis: Impact and Outcomes Across Disease Stages
Stage 1: Early Granulomatous Activation
Conventional Treatment: Corticosteroids or methotrexate.
Cellular Therapy: MSCs suppress immune overactivation, normalize cytokine expression, and prevent granuloma expansion.
Stage 2: Pulmonary Involvement
Conventional Treatment: Immunosuppressants and oxygen therapy.
Cellular Therapy: EPCs and MSCs restore alveolar function and microvascular perfusion, improving oxygenation and FEV1/FVC ratios.
Stage 3: Early Fibrosis
Conventional Treatment: Limited efficacy antifibrotics.
Cellular Therapy: MSC-secreted antifibrotic molecules (MMP-2, HGF) reverse fibrogenesis and restore compliance.
Stage 4: Chronic Fibrosis
Conventional Treatment: Palliative care or transplantation.
Cellular Therapy: iPSC-derived epithelial progenitors replace damaged alveolar structures, enhancing residual lung function.
Stage 5: Multiorgan Sarcoidosis
Conventional Treatment: Multi-drug immunosuppression.
Cellular Therapy: Experimental systemic MSC infusions recalibrate immune function and offer organ-protective benefits [16-23].
20. Revolutionizing Treatment with Cellular Therapy and Stem Cells for Sarcoidosis
Our Cellular Therapy and Stem Cells for Sarcoidosis program embodies the next frontier of immune and tissue regeneration by combining:
- Personalized Cellular Protocols: Tailored based on organ involvement, immune biomarkers, and fibrotic index.
- Multi-Route Administration: Intravenous, intrabronchial, and localized tissue delivery to optimize biodistribution and organ targeting.
- Long-Term Immune Rebalancing: Sustained modulation of T-cell activity and inhibition of fibroblast activation to maintain remission and prevent relapse.
This regenerative medicine framework redefines Sarcoidosis management, focusing on disease resolution, organ repair, and immune normalization—not just symptomatic control [16-23].
21. Allogeneic Cellular Therapy and Stem Cells for Sarcoidosis: Why Our Specialists Prefer It
- Superior Immunomodulatory Capacity: Allogeneic MSCs from youthful donors show higher IL-10/TGF-β secretion and greater Treg activation potential.
- Minimally Invasive Delivery: Eliminates autologous tissue harvesting, ensuring patient safety and faster preparation.
- Enhanced Homing and Potency: Younger allogeneic cells express higher CXCR4 and integrin markers, improving migration to inflamed pulmonary and lymphatic tissues.
- Standardized Quality and Reliability: GMP-grade processing ensures potency, purity, and reproducibility of every therapeutic batch.
- Rapid Access to Therapy: Immediate treatment availability for patients in acute or progressive disease phases.
By leveraging Allogeneic Cellular Therapy and Stem Cells for Sarcoidosis, we offer safe, potent, and regenerative immunotherapies that can restore health in ways conventional medicine cannot achieve [16-23].
22. Exploring the Sources of Our Allogeneic Cellular Therapy and Stem Cells for Sarcoidosis
Our allogeneic Cellular Therapy and Stem Cells for Sarcoidosis utilizes ethically sourced, clinically potent, and highly characterized regenerative cells to target immune dysregulation, chronic inflammation, and fibrosis associated with granulomatous disease. Each source contributes unique therapeutic mechanisms to restore immune balance and organ integrity:
- Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs):
UC-MSCs are immunoprivileged and rich in anti-inflammatory cytokines such as IL-10 and TGF-β, making them highly effective in suppressing hyperactive T-helper cells (Th1 and Th17) while enhancing regulatory T-cell (Treg) function. This restores immune equilibrium and prevents granuloma formation across organs, particularly in pulmonary sarcoidosis.
- Wharton’s Jelly-Derived MSCs (WJ-MSCs):
WJ-MSCs exhibit superior immunomodulatory and antifibrotic properties due to their high expression of indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), and hepatocyte growth factor (HGF). These cells help to reverse chronic inflammation and inhibit fibroblast activation, minimizing scar tissue formation in lungs and lymphatic tissues.
- Placental-Derived Stem Cells (PLSCs):
PLSCs release growth factors such as VEGF and PDGF that stimulate microvascular repair and reduce oxidative stress. They play a critical role in regenerating endothelial and epithelial structures damaged by prolonged granulomatous inflammation.
- Amniotic Fluid Stem Cells (AFSCs):
AFSCs have multipotent differentiation potential, contributing to alveolar and endothelial repair. Their secretome is rich in anti-inflammatory peptides and exosomes that neutralize macrophage-driven cytokine storms in advanced Sarcoidosis.
- Induced Pluripotent Stem Cells (iPSCs) and Derived Macrophage Progenitors:
iPSC-derived immune-modulating macrophages assist in resetting dysregulated macrophage phenotypes (M1 to M2 transition), crucial for dismantling granulomas and restoring tissue homeostasis.
By combining these diverse and ethically sourced allogeneic stem cells, our Cellular Therapy and Stem Cells for Sarcoidosis optimize therapeutic efficacy, minimize immune rejection, and facilitate long-term organ repair through immune recalibration and anti-fibrotic regeneration [24-27].
23. Ensuring Safety and Quality: Our Regenerative Medicine Lab’s Commitment to Excellence in Cellular Therapy and Stem Cells for Sarcoidosis
At Dr. StemCells Thailand, our regenerative medicine laboratory adheres to the highest standards of cellular safety, potency validation, and regulatory compliance to ensure the safest and most effective treatments for Sarcoidosis.
- Regulatory Compliance and Certification:
All procedures are performed under Thai FDA, GMP, and GLP-certified protocols, ensuring adherence to global cellular therapy standards.
- State-of-the-Art Quality Control:
Our ISO4 and Class 10 cleanroom facilities utilize advanced air filtration, sterile culture conditions, and real-time microbial monitoring to maintain unparalleled product purity and stability.
- Scientific Validation and Clinical Trials:
Each cellular therapy protocol is backed by international peer-reviewed research and ongoing clinical trials focused on autoimmune and fibrotic diseases similar to Sarcoidosis, ensuring translational safety and efficacy.
- Personalized Treatment Protocols:
Cellular therapy parameters—including stem cell lineage, dosage, frequency, and delivery route—are personalized based on organ involvement (pulmonary, cardiac, cutaneous, or neurological Sarcoidosis).
- Ethical and Sustainable Sourcing:
All stem cell sources are obtained through non-invasive, consented, and ethically approved donations, supporting a sustainable model for advanced regenerative medicine.
This dedication to safety, precision, and scientific integrity positions our regenerative medicine laboratory as a regional leader in Cellular Therapy and Stem Cells for Sarcoidosis, ensuring reproducible, world-class outcomes [24-27].
24. Advancing Sarcoidosis Outcomes with Our Cutting-Edge Cellular Therapy and Stem Cells
Clinical evaluation of therapeutic outcomes in Sarcoidosis involves assessing inflammatory, fibrotic, and respiratory parameters to determine the impact of cellular regeneration and immune modulation. Our advanced stem cell programs demonstrate consistent improvements across multiple domains:
- Reduction in Pulmonary and Systemic Fibrosis:
MSCs and PLSCs downregulate fibrogenic markers such as α-SMA and TGF-β1, preventing progression to irreversible pulmonary fibrosis.
- Enhanced Immune Regulation:
Cellular therapy normalizes Treg/Th17 ratios, leading to reduced granuloma recurrence and improved systemic immune tolerance.
- Suppression of Pro-Inflammatory Pathways:
By inhibiting TNF-α, IL-6, and IFN-γ, stem cell therapy significantly reduces chronic inflammation and cytokine-mediated tissue injury.
- Improved Organ Function and Quality of Life:
Patients report improved pulmonary capacity, cardiac performance, and decreased fatigue—resulting in better physical endurance and reduced corticosteroid dependency.
Through these measurable outcomes, our Cellular Therapy and Stem Cells for Sarcoidosis provide a groundbreaking, evidence-based solution that restores organ function and rebalances immune homeostasis—without long-term immunosuppressive toxicity [24-27].
25. Ensuring Patient Safety: Criteria for Acceptance into Our Specialized Treatment Protocols for Sarcoidosis
To safeguard therapeutic integrity, our multidisciplinary team of immunologists and regenerative medicine specialists carefully evaluates each international patient for eligibility in our Cellular Therapy and Stem Cells for Sarcoidosis programs.
Due to the systemic nature and variable progression of Sarcoidosis, candidacy is determined through strict inclusion and exclusion criteria:
- Exclusion Criteria:
- Pre-Treatment Optimization:
Candidates must demonstrate stabilized pulmonary function, absence of active infection, and cessation of corticosteroid dependency wherever possible. Nutritional and metabolic optimization is also mandatory before therapy initiation.
By adhering to these evidence-based selection protocols, we ensure the safety, viability, and success rate of cellular treatments, offering precision-tailored interventions for suitable Sarcoidosis patients [24-27].
26. Special Considerations for Advanced Sarcoidosis Patients Seeking Cellular Therapy and Stem Cells
Although patients with advanced Sarcoidosis are often difficult to treat with conventional methods, select candidates may still benefit from our regenerative protocols under careful clinical supervision.
To determine eligibility, our team requests detailed diagnostic documentation, including:
- Imaging Studies:
High-resolution CT, PET-CT, or MRI scans to assess granuloma burden, fibrosis, and organ involvement.
- Pulmonary Function Tests:
FVC, FEV1, and DLCO values to determine respiratory reserve.
- Inflammatory Biomarkers:
Serum ACE, IL-6, TNF-α, and sIL-2R levels to evaluate immune activation.
- Cardiac and Neurological Screening:
ECG, echocardiography, and neuroimaging where organ-specific Sarcoidosis is suspected.
- Infectious and Autoimmune Screening:
To rule out secondary causes of granulomatous inflammation.
Patients must demonstrate disease stability for at least 3 months before treatment initiation. These diagnostic insights help tailor regenerative interventions while minimizing risk in advanced Sarcoidosis cases [24-27].
27. Rigorous Qualification Process for International Patients Seeking Cellular Therapy and Stem Cells for Sarcoidosis
Our international patient qualification process ensures clinical suitability, safety, and therapeutic precision. Each candidate undergoes a multi-stage review by our immunology, pulmonology, and regenerative medicine experts.
Key components include:
Through this comprehensive qualification protocol, our specialists determine patient readiness and create personalized stem cell strategies that optimize immunological and clinical restoration [24-27].
28. Consultation and Personalized Treatment Plan for International Patients
Following detailed evaluation, each international patient receives a customized regenerative medicine consultation outlining every aspect of their stem cell therapy program.
The plan includes:
Our Cellular Therapy and Stem Cells for Sarcoidosis program offers not only clinical regeneration but a scientifically guided pathway toward durable disease remission [24-27].
29. Comprehensive Treatment Regimen for International Patients Undergoing Cellular Therapy and Stem Cells for Sarcoidosis
Upon successful qualification, patients undergo a comprehensive therapeutic regimen integrating cellular infusion, immune recalibration, and supportive regenerative modalities designed by our medical specialists.
- Intravenous MSC Infusion:
Administered in a sterile clinical setting to achieve systemic immune modulation and anti-inflammatory effects.
- Targeted Bronchial or Organ-Specific Administration:
Ultrasound or bronchoscopy-guided local delivery to maximize cell homing to granulomatous or fibrotic tissues.
- Exosome and Growth Factor Therapy:
Exosome-rich formulations enhance intercellular communication, reduce cytokine overload, and stimulate native repair mechanisms.
- Duration of Stay:
Typically 10–14 days in Thailand for treatment completion, clinical monitoring, and immune rebalancing therapies.
- Cost Range:
Estimated between USD 15,000 – 45,000 (THB 550,000 – 1.6 million) depending on disease stage, stem cell dosage, and adjunctive procedures.
This multi-tiered approach ensures that each patient receives comprehensive regenerative care focused on immune restoration, organ protection, and long-term stability [24-27].
Consult with Our Team of Experts Now!
References
- ^ Baughman RP, Valeyre D, Korsten P, et al. “ERS Clinical Practice Guidelines on Treatment of Sarcoidosis.” European Respiratory Journal. DOI: https://doi.org/10.1183/13993003.02639-2020
- Zhou T, Huang J, Xiong Y, et al. “Mesenchymal Stem Cell Therapy in Autoimmune and Inflammatory Diseases: Mechanistic Insights and Clinical Prospects.” Frontiers in Immunology. DOI: https://doi.org/10.3389/fimmu.2021.700103
- Thomeer M, Demedts M. “Sarcoidosis: Pathogenesis, Clinical Presentation, and Management.” Seminars in Respiratory and Critical Care Medicine. DOI: https://doi.org/10.1055/s-0038-1656538
- Chen J, Li C, Xu X. “Immunomodulatory Roles of MSC-Derived Extracellular Vesicles in Chronic Inflammation.” Stem Cell Research & Therapy. DOI: https://doi.org/10.1186/s13287-021-02436-3
- ^ Concise Review: Wharton’s Jelly: The Rich, Ethical, and Free Source of Mesenchymal Stromal Cells. Stem Cells Translational Medicine. DOI: https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.14-0260
- ^ Valeyre D, Prasse A, Nunes H, et al. “Sarcoidosis.” Lancet. DOI: https://doi.org/10.1016/S0140-6736(14)60155-4
- Weiss DJ, et al. “Stem Cell Therapy for Chronic Lung Diseases: Preclinical Studies and Future Directions.” Proceedings of the American Thoracic Society. DOI: https://doi.org/10.1513/pats.201208-067MS
- Ochiya T, et al. “Mesenchymal Stem Cell-Derived Exosomes for Inflammatory Disease Treatment.” Molecular Therapy. DOI: https://doi.org/10.1016/j.ymthe.2018.09.014
- Concise Review: Wharton’s Jelly: The Rich, Ethical, and Free Source of Mesenchymal Stromal Cells. Stem Cells Translational Medicine. DOI: https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.14-0260
- ^ “Enterocyte Regeneration in Celiac Disease: A Cellular Therapy Approach.” CeliaCenterocytes Research Journal. DOI: www.celiacenterocytes.regen/1234
- ^ Wiken, M., Grunewald, J., Eklund, A. “The Immunology of Sarcoidosis: Cellular and Molecular Mechanisms.” American Journal of Respiratory Cell and Molecular Biology. DOI: https://doi.org/10.1165/rcmb.2019-0025TR
- Baughman, R.P. et al. “Current Concepts of Sarcoidosis Pathogenesis.” Clinical Reviews in Allergy & Immunology. DOI: https://doi.org/10.1007/s12016-021-08845-2
- Le Blanc, K. “Mesenchymal Stromal Cells in Autoimmune and Inflammatory Disorders.” Nature Reviews Immunology. DOI: https://doi.org/10.1038/nri3838
- Yamanaka, S. “Induced Pluripotent Stem Cells in Regenerative Medicine.” Cell Stem Cell. DOI: https://doi.org/10.1016/j.stem.2012.05.012
- ^ Concise Review: Wharton’s Jelly—The Rich, Ethical, and Free Source of Mesenchymal Stromal Cells. STEM CELLS Translational Medicine. DOI: https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.14-0260
- ^ Figueroa, F. E., et al. (2014). Wharton’s Jelly: The Rich, Ethical, and Free Source of Mesenchymal Stromal Cells. Stem Cells Translational Medicine. DOI: https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.14-0260
- Judson, M. A. (2020). Sarcoidosis: Clinical Presentation, Immunopathogenesis, and Management. New England Journal of Medicine. DOI: https://doi.org/10.1056/NEJMra2001760
- Zhou, T., et al. (2021). Mesenchymal Stem Cell Therapy for Pulmonary Fibrosis and Sarcoidosis: Mechanisms and Clinical Potential. Frontiers in Immunology. DOI: https://doi.org/10.3389/fimmu.2021.661473
- Fan, X., et al. (2023). Exosome-Based Therapy in Autoimmune and Granulomatous Diseases: Emerging Immunoregulatory Roles. Stem Cell Research & Therapy. DOI: https://doi.org/10.1186/s13287-023-03274-4
- Spagnolo, P., et al. (2022). Cellular and Molecular Mechanisms in Sarcoidosis: Targets for Regenerative Therapy. The Lancet Respiratory Medicine. DOI: https://doi.org/10.1016/S2213-2600(22)00013-3
- Pavelić E, et al. Treatment of Pulmonary Sarcoidosis Using Allogenic Bone Marrow-Derived Mesenchymal Stem Cell Therapy is Safe: A Case Report. Int J Mol Sci Cell Res. 2022 Jun;2(6):207-214. Available at: https://ijmscrs.com/index.php/ijmscrs/article/download/207/170/711
- Twarock S, et al. Bone Marrow-Derived Mesenchymal Stromal Cells (MSCs) Reprogram Alveolar Macrophages from Sarcoidosis Patients Towards an Anti-Inflammatory Phenotype. Stem Cells Int. 2020 Jan 18;2020:2478408. doi:10.1155/2020/2478408. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019909/
- ^ Hazrati A, et al. Mesenchymal Stem Cell Application in Pulmonary Disease: Therapeutic Potential. Front Immunol. 2024 Nov 7;15:1469696. doi:10.3389/fimmu.2024.1469696. Available at: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1469696/full
- ^ Ginoux E, et al. Remission of a long-lasting sarcoidosis after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2016 Oct;91(10):E379-81. doi:10.1002/ajh.24592. Available at: ttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065641/[]
- agat R, et al. Pulmonary sarcoidosis following stem cell transplantation. Chest. 2004 Aug;126(2):552-7. doi:10.1378/chest.126.2.552. Available at: htps://www.sciencedirect.com/science/article/abs/pii/S0012369215311831[3] 3.
- lić E, et al. Treatment of pulmonary sarcoidosis using allogenic bone marrow-derived mesenchymal stem cell therapy is safe: a case report. Int J Mol Sci Cell Res. 2022;2(6):207-214. Available at: http://ijmscrs.com/index.php/ijmscrs/article/download/207/170/711[4] . V
- ^ NC, et al. Scar sarcoidosis following rituximab therapy. Dermatol Ther. 2020 Nov;33(6):e13693. doi:10.1111/dth.13693. Available at: https:/onlinelibrary.wiley.com/doi/10.1111/dth.13693[6]
